Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Inclusion Criteria: * Histologically confirmed malignancy at either original diagnosis or relapse, including the following: * Solid tumor, including primary CNS tumors * Neurologic deficits in patients with CNS tumors must have been relatively stable for ≥ 1 week * Patients with CNS tumors must be on stable or decreasing doses of dexamethasone for the past 7 days * Histology requirement waived for intrinsic brain stem tumors * Lymphoma * Measurable or evaluable disease * No known curative therapy or no therapy proven to prolong survival with an acceptable quality of life exists * Patients with known bone marrow metastases are eligible for study but are not evaluable for hematologic toxicity * Not known to be refractory to red blood cell or platelet transfusions * Karnofsky performance score (PS) 60-100% (\> 10 years of age) or Lansky PS 60-100% (≤ 10 years of age) * Absolute neutrophil count ≥ 1,000/mm³ * Platelet count ≥ 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to study enrollment) * Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed) * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine based on age as follows: * No greater than 0.8 mg/dL (≤ 5 years of age) * No greater than 1.0 mg/dL (6 to 10 years of age) * No greater than 1.2 mg/dL (11 to 15 years of age) * No greater than 1.5 mg/dL (\> 15 years of age) * Bilirubin ≤ 1.5 times upper li…